Perspectives on the OlympiA study of adjuvant olaparib in early breast cancer | Nadine Tung

OlympiA: Adjuvant olaparib delays recurrence of BRCA-mutant breast cancer | Judy GarberПодробнее

OlympiA: adjuvant olaparib in gBRCAm, HER2-negative, high-risk, early breast cancerПодробнее

OlympiA: adjuvant olaparib following chemo significantly improves IDFSПодробнее

Breast Cancer Breakthrough - Prof Andrew Tutt on the OlympiA trialПодробнее

OLYMPIA TRIAL LYNPARZA STOPS EARLY BREAST CANCER FROM COMING BACKПодробнее

OLYMPIA TrialПодробнее

Dr. Tung Discusses the Role of Olaparib in Breast CancerПодробнее

ASCO 2021 - Highlights on shifting PARPi to Early Breast Cancer: The OlympiA studyПодробнее

Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and G...Подробнее

DORA: durvalumab and olaparib in platinum treated advanced TNBCПодробнее

TBCRC 048: olaparib monotherapy in metastatic breast cancerПодробнее

Dr. Tripathy on Impact of Olaparib Approval in BRCA-Positive Breast CancerПодробнее

ELEANOR interim analysis: real-world study of adjuvant neratinib in HER2+/HR+ early breast cancerПодробнее

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer wit...Подробнее

PARP in Breast CancerПодробнее

Quality of life results from OlympiAПодробнее

Exploring the role of olaparib and treatment intensification in breast cancerПодробнее

State of the art of surgery in patients with early breast cancerПодробнее

Dr. Robson on the Toxicity Profile of Olaparib in Breast CancerПодробнее